Actively Recruiting
Randomized Placebo-Controlled Study to Assess Safety and Effectiveness of SG301 SC Injection for Primary Immune Thrombocytopenia in Adults
Led by Hangzhou Sumgen Biotech Co., Ltd. · Updated on 2026-09-09
60
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of SG301 SC Injection in adults with primary immune thrombocytopenia ITP, a condition characterized by low platelet counts. This Phase II, multicenter, randomized, double-blind, placebo-controlled study aims to assess the treatments impact while also examining how the drug behaves in the body and the immune response it may trigger. Participants will be randomly assigned to one of three groups a low dose SG301 group, a high dose SG301 group, or a placebo group. Each participant will receive subcutaneous injections once a week for eight weeks, totaling eight doses. Background therapies that participants are on at stable doses prior to the study are expected to continue throughout the trial. During the study, participants will be monitored for safety through the incidence of treatment-emergent adverse events up to 24 weeks and for treatment response at week 8. Assessments will include platelet counts and evaluations of physical performance. The study duration includes the treatment period and follow-up, with ongoing monitoring to evaluate drug effects and participant health.
CONDITIONS
Brief Title
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
Research Team
S
Songping Ao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here